FDA Poorly Equipped To Enforce Off-Label Prescription Drug Marketing Rules, GAO Report Finds

Main Category: Pharma Industry / Biotech Industry
Also Included In: Pharmacy / Pharmacist;  Regulatory Affairs / Drug Approvals
Article Date: 29 Jul 2008 - 12:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (2 votes)

Healthcare Prof:5 stars

5 (1 votes)


FDA takes an average of seven months to issue warnings to pharmaceutical companies that market medications for off-label uses, and those companies take an average of four months to address the violations, according to a draft report compiled by the Government Accountability Office, the AP/Minneapolis Star Tribune reports. The report found that FDA has no employees specifically assigned to monitor whether pharmaceutical companies market medications for off-label uses.

According to the report, FDA's Division of Drug Marketing, Advertising and Communications, which has 44 employees assigned to review prescription drug ads, monitors marketing for off-label use. The division examined about 68,000 prescription drug ads in total last year, the report found. The division seeks to prioritize misrepresentations in prescription drug ads that could affect human health but lacks a system to track all information received by FDA, according to the report. From 2003 to 2007, the division issued 42 notices of potential violations related to off-label use, most of which prompted pharmaceutical companies to end misrepresentations in prescription drug ads.

Sen. Chuck Grassley (R-Iowa), who requested the report, in a statement said that FDA "isn't keeping track of how drugs are marketed for off-label use, even though marketing for off-label use is illegal and it's the FDA's job to enforce that law." He added, "As a result, drugmakers aren't being held accountable for promoting unapproved use of medicine and patient safety is diminished" (Alonso-Zaldivar, AP/Minneapolis Star Tribune, 7/27).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "FDA Poorly Equipped To Enforce Off-Label Prescription Drug Marketing Rules, GAO Report Finds." Medical News Today. MediLexicon, Intl., 29 Jul. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/116428.php>

APA
Kaiser. (2008, July 29). "FDA Poorly Equipped To Enforce Off-Label Prescription Drug Marketing Rules, GAO Report Finds." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/116428.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »